SAINT LAURENT, Quebec, April 28, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a Canadian drug delivery company focused on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (“RedHill”), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today announced the commencement of a comparative bioavailability clinical study comparing their anti-migraine VersaFilm™ Product to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application (“MAA”) for the anti-migraine VersaFilm™ Product, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.
Help employers find you! Check out all the jobs and post your resume.
